These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30676731)

  • 1. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
    Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
    Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
    Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
    Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.
    Guo C; Hao LJ; Yang ZH; Chai R; Zhang S; Gu Y; Gao HL; Zhong ML; Wang T; Li JY; Wang ZY
    Exp Neurol; 2016 Jun; 280():13-23. PubMed ID: 26996132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
    Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
    J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local delivery of iron chelators reduces in vivo remodeling of a calcium phosphate bone graft substitute.
    Drager J; Sheikh Z; Zhang YL; Harvey EJ; Barralet JE
    Acta Biomater; 2016 Sep; 42():411-419. PubMed ID: 27449336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
    Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
    J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
    Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
    Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
    Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
    Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
    Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression.
    Miyake K; Nishioka M; Imura S; Batmunkh E; Uto Y; Nagasawa H; Hori H; Shimada M
    Exp Cell Res; 2012 Aug; 318(13):1554-63. PubMed ID: 22472348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferoxamine-induced increase in the intracellular iron levels in highly aggressive breast cancer cells leads to increased cell migration by enhancing TNF-α-dependent NF-κB signaling and TGF-β signaling.
    Liu P; He K; Song H; Ma Z; Yin W; Xu LX
    J Inorg Biochem; 2016 Jul; 160():40-8. PubMed ID: 27138103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells.
    Elstner A; Holtkamp N; von Deimling A
    Clin Exp Metastasis; 2007; 24(1):57-66. PubMed ID: 17357815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
    Kuban-Jankowska A; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Wozniak M
    Anticancer Res; 2017 Sep; 37(9):4799-4806. PubMed ID: 28870898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.